Abstract: Water-soluble refill dose articles for forming a cleanser have a water-soluble film defining a first compartment enclosing a first composition and a second compartment enclosing a second composition, which are individual separate articles or are part of an integral article. The first composition has a rheology modifier, a first surfactant, 10% or less by weight water, 20% or less by weight glycol, and the first surfactant does not activate the rheology modifier. The second compartment has an alkaline substance that when mixed with the first composition and water activates the rheology modifier to increase the viscosity of a resulting cleanser and 10% or less by weight water. When the article is diluted in water at a 1:1 to 1:20 ratio, it produces a cleanser having a viscosity within a range of 2000 cps to 50,000 cps.

Abstract: Oral care compositions containing a stannous salt and sodium tripolyphosphate are provided where stannous tripolyphosphate ionic intermediates comprise less than about 1% of the compositions. Tetrasodium pyrophosphate, a methylvinyl ether-maleic anhydride copolymer and/or a silica oral polishing agent may be added for further efficacy. In a single phase blend, the oral care composition may be effectively limited to comprise less than about 10% water. In a dual-phase blend, a mixture having the stannous salt in a first phase and the sodium tripolyphosphate in a second phase may be generated from a dual chamber storage tube (with each phase provided from a separate chamber) immediately prior to dental care usage.

Abstract: This invention is directed to an effect pigment dispersion comprising a PVD-aluminum pigment, a leafing additive and an oil suitable for cosmetic skin care or color cosmetic applications, wherein a) the amount of the PVD-aluminum pigment is in a range of 8 to 30 wt.-%, b) the amount of the oil is in a range of 70 to 90 wt.-%, each based on the total weight of the effect pigment dispersion and c) the leafing additive is partly adsorbed on the surface of the PVD-aluminum pigment and partly an excess additive dissolved in the oil, wherein the amount of excess leafing additive is in a range of 0 to 25 wt.-%, based on the weight of PVD aluminum pigment. Further cosmetic skin care of color cosmetic formulations containing this effect pigment dispersion are described.

Abstract: Semiconductor colloids grafted covalently with an antioxidant, the colloids being semiconductor colloids constituted by at least one element chosen from the group comprising C, Si, Ge, Sn, S, Se, Te, B, N, P, As, Al, Sb, Ga, In, Cd, Zn, O, Cu, Cl, Pb, Tl, Bi, Ti, U, Ba, Sr, Li, Nb, La, I, Mo, Mn, Ca, Fe, Ni, Eu, Cr, Br, Ag, Pt, Hg, and combinations thereof.

Abstract: Provided is an oral composition that has excellent stability over time although a hydrocarbon oil is contained therein. Specifically provided is an oral composition comprising a hydrocarbon oil, a polyhydric alcohol, and a surfactant, the oral composition comprising (1) glycerol, and a polyglycerol fatty acid ester and/or an alkyl glucoside, (ii) propanediol, and a polyoxyethylene hardened castor oil and/or a polyoxyethylene hardened castor oil fatty acid ester, (iii) butylene glycol, and a polyoxyethylene alkyl ether and/or a polyoxyethylene hardened castor oil fatty acid ester, or (iv) polyethylene glycol and a polyoxyethylene hardened castor oil fatty acid ester.

Abstract: Disclosed are cosmetic compositions and skin care products that are stabilized against lipid chain auto-oxidation. In particular, this invention substitutes a portion of polyunsaturated fatty acids used in cosmetic compositions and skin care products with a corresponding deuterated polyunsaturated fatty acid.

Abstract: Compositions in the prevention and treatment of skin diseases or associated disorders, inflammation or inflammatory diseases or disorders, include at least one inhibitor of glycosphingolipid synthesis.

Abstract: The present disclosure relates to a composition containing at least one chelating agent, its use, a hair dyeing and/or bleaching composition which contains this composition, a kit for dyeing and/or bleaching hair which comprises the composition, a method for dyeing and/or bleaching the hair, and a method for hair cosmetic treatment which comprise the application of the composition.

Abstract: The present invention relates to a detergent containing or prepared by blending: (A) an anionic surfactant; (B) an aminopolyether-modified silicone containing a polyoxyalkylene structure and satisfying the following formula (I); and (C) an organic acid, wherein a mass ratio [(A)/(B)] of the component (A) to the component (B) is less than 25, and a mass ratio [(A)/(C)] of the component (A) to the component (C) is 30 or more and 3,000 or less: 0.01?Si/AO?1.6??(I) (in the formula (I), Si represents a molar number of a silicon atom in the component (B), and AO represents an oxyalkylene average addition molar number in the component (B)).

Abstract: A cosmetic composition is provided. The cosmetic composition comprises a carboxylic acid modified silicone (A) that has a specific chemical structure and is liquid at room temperature. The cosmetic composition also comprises an oil agent (B). The cosmetic composition generally provides a cosmetic film having excellent water resistance, and can be easily removed by normal soap and water.

Abstract: Cellulite eradication methods for substantially eradicating cellulite from a cellulite treatment site on the skin of a patient may include injecting a collagen degrading enzyme into a subcutaneous space and into contact with cellulite band septa in the skin of the patient.

Abstract: A multi-action skin-lightening cosmetic composition is provided. The cosmetic composition comprises ascorbic acid delivered in a stable form in a high concentration and, optionally, other complementary active ingredients.

Abstract: Disclosed is a sterile and topical cosmetic composition including, in a physiologically acceptable medium, an efficient amount of crosslinked hyaluronic acid and an efficient amount of polyacrylate crosspolymer-6, Also disclosed is the use of said composition for reducing the signs of skin aging and/or to car the skin of a subject who has previously been subjected to one or more aesthetic and/or cosmetic intervention(s); and to a cosmetic process for caring the skin comprising at least the step of applying topically, on the skin surface(s) to be cared, an effective amount of said composition, to a subject who has previously been subjected to one or more aesthetic and/or cosmetic intervention(s).

Abstract: An oral care composition is disclosed. The oral care composition includes (A) an adhesive agent comprising an alkylated polyvinylpyrrolidone, (B) a miscibility component comprising an acrylic acid-acrylate copolymer, and (C) a plasticizer comprising a polyalkylene glycol. An oral care device is also disclosed. The oral care device includes an oral care layer comprising the oral care composition and a whitening agent. A method of preparing the oral care device is also disclosed, and includes extruding the oral care composition to give the oral care layer, and preparing a laminate comprising the oral care layer. The method may further include processing the laminate to give the oral care device, which may be prepared as an oral care strip or an oral care tray.

Abstract: The present invention relates to sulfate-free cosmetic rinse-off compositions which comprises a hyperbranched copolymer of the monomers dodecenyl succinic acid anhydride, diisopropanol amine and bis-dimethylamino-propyl amine having quaternary terminal groups.

Abstract: Provided is a method for treating hair damage by contacting the hair with an effective amount of an epoxysilicone. The method may be used for treating hair damage caused by a hair altering process that is capable of damaging hair, for example, hair lightening/bleaching procedures, hair relaxing procedures, hair dyeing procedures, hair permanent waving, and hair smooting. Also provided is a composition and a product, which include a hair damage treating effective amount of the epoxysilicone.

Abstract: The present invention relates to a detergent containing or prepared by blending: (A) an anionic surfactant; (B) an aminopolyether-modified silicone containing a polyoxyalkylene structure and satisfying the following formula (I); and (C) an organic acid, wherein a mass ratio [(A)/(B)] of the component (A) to the component (B) is 25 or more, and a mass ratio [(A)/(C)] of the component (A) to the component (C) is 1 or more and 3,000 or less: 0.01?Si/AO?1.6??(I) (in the formula (I), Si represents a molar number of a silicon atom in the component (B), and AO represents an oxyalkylene average addition molar number in the component (B)).

Abstract: The present invention relates to a composition, especially comprising a physiologically acceptable medium, especially for coating keratin materials, more particularly for making up and/or caring for keratin materials such as the skin, and containing at least one silicone/polyurea copolymer and/or a silicone/polyurethane copolymer and/or a silicone/polyurethane copolymer of following formula (I): •b) at least one volatile alkane; and •c) at least one monoalcohol comprising from 2 to 8 carbon atoms; and •d) at least one silicone resin. The invention also relates to a process for coating keratin materials, more particularly for making up and/or caring for keratin materials such as the skin, characterized in that it comprises the application to the keratin materials of a composition as defined previously. The present invention also relates to a cosmetic assembly comprising •a composition as defined previously •a device for applying said composition to the keratin materials.

Abstract: A mask substrate and a kit including the same are provided. The mask substrate includes a substrate layer; the substrate layer is prepared by freeze-drying a plant slice having a predetermined thickness under a predetermined condition. After the mask substrate is rehydrated with an infiltrating liquid, a surface of the mask substrate is able to be applied to the skin of an individual. In one of the aspects, the mask substrate may effectively absorb water or essence liquid through a natural fiber pore structure, which may release active substances contained in the substrate to improve the skin moisturizing effect.

Abstract: An anti-wrinkle cosmetic composition comprises a Kava extract, one or more penetration and other anti-wrinkle agents. The Kava extract is extracted from Piper Methysticum root, leaf, stem, or their combinations.

Abstract: The present invention relates to a method of preparing a culture broth of neural stem cells, having excellent abilities of reducing skin wrinkles or increasing skin elasticity, the culture broth comprising high concentrations of TIMP-1 and TIMP-2 capable of inhibiting the expression and activity of matrix metalloproteinases (MMPs) involved in collagen decomposition in the dermis. The culture broth of neural stem cells according to the present invention, which comprises, as active ingredients, high concentrations of TIMP-1 and TIMP-2 and low concentrations of various MMPs, restores the synthesis of collagen and elastin by suppressing the expression and activity of MMPs inhibiting collagen formation, and thus is useful as a composition for reducing skin wrinkles or increasing skin elasticity.

Abstract: The present invention relation to an oral care composition comprising a cannabinoid and at least one pharmaceutical active component is provided in which the at least one pharmaceutical active component improves oral health beyond benefits provided by the at least one cannabinoid alone. The at least one pharmaceutical active component can be Manuka honey. The oral care composition can be used in an oral care product for whitening or bleaching teeth.

Abstract: The present invention relates generally to methods and compositions useful for application to skin and hair comprising saccharide isomerate, Alteromonas ferment extract, and a dermatologically acceptable vehicle, wherein the composition is capable of moisturizing and/or improving the appearance and/or condition of skin and/or hair.

Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual administration preparation can avoid the first-pass effect of the liver, and samples feature good stability, convenience of transport and of use, among other advantages.

Abstract: Disclosed are compositions and methods for microneedle patches comprising copolymer designed for glucose triggered insulin delivery. In one aspect, disclosed herein are microneedle patches comprising insulin loaded copolymers; wherein the insulin dissociates from the microneedle in an hyperglycemic environment; wherein the copolymer comprises poly(N-vinylpyrrolidone-co-2-(dimethylamino)ethyl acrylate-co-3-(acrylamido)phenylboronic acid and methods of their use.

Abstract: Compositions and methods are provided for lamellar and defect reconstruction of corneal stromal tissue using biomaterials that form a defined gel structure in situ. Such gels can serve as cellular or acellular lamellar substitutes to reconstruct corneal stroma, facilitate matrix remodeling, and support multilayered re-epithelialization of wounded corneal stromal tissue, as well delivery vehicles for cells, biomolecules, and/or pharmaceutical agents to wound sites throughout the body.

Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

Abstract: Alprazolam formulated as an inhaled condensation aerosol and method for treating epilepsy and/or seizures.

Abstract: The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and —a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 15 4.0 ?m as measured with a 0.

Abstract: A concentrate for preparation of a gel for one of a medical device, a medical product, or a first aid product includes at least one gelling agent, at least one humectant, and at least one preservative. A gel is prepared from water and the. A method of preparing the gel includes the step of admixing water and the concentrate. The concentrate of the present disclosure is configured to be added to be sold, transported, and stored in concentrated form to ease transportation, decrease the cost of transportation and storage, optimize storage space, minimize product cost, ease use of product, militate against risk of microbial contamination, and decrease risk of product breakdown with exposure to UV light.

Abstract: The present invention relates to a lyophilized pharmaceutical composition for reconstitution in an aqueous carrier liquid comprising: a) liposome-forming structures comprising i. a therapeutically effective amount of cyclosporine A (CsA); ii. a membrane forming substance selected from the group of phospholipids; and iii. a solubility enhancing substance selected from the group of non-ionic surfactants; and b) at least one disaccharide selected from the group consisting of saccharose, lactose and trehalose, wherein the at least one disaccharide is present in an amount of at least 40 wt.-% with regard to the total weight of the lyophilized composition.

Abstract: Processes for preparing neutral liposomes include adding a hydrophobic solution of liposome lipid bilayer precursors and a nucleic acid condenser to an aqueous composition of a nucleic acid condenser and a biologically active ingredient and then, isolating the liposomes. The liposomes are formed from noncationic lipids and encapsulate the biologically active ingredient as a core composition and entrap some of the biologically active ingredient on the exterior surface of the liposome. The liposomes have the nucleic acid condensers and/or cell penetrating peptides attached to the exterior surface of the lipid bilayer. One or more divalent cations are present in the solution with the liposome and remain in solution once the liposomes form.

Abstract: Solid lipid nanoparticles (SLNs) and suspensions thereof in an aqueous phase are provided, in which the SLNs have high content of oil-soluble pigment and high stability. A food product, such as a beverage, comprising said SLNs is also provided.

Abstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

Abstract: The present application provides a method of making a particle comprising (i) obtaining a first solution comprising a negatively charged polysaccharide; (ii) obtaining a second solution comprising a positively charged polysaccharide; and (iii) mixing the first solution and the second solution to obtain a suspension comprising the particle. The present application also provides a method of making a therapeutic particle, comprising: (i) obtaining a solution comprising a therapeutic protein; (ii) obtaining a first suspension comprising the particle comprising a negatively charged polysaccharide and a positively charged polysaccharide, and (iii) mixing the solution of the therapeutic protein and the first suspension to obtain a second suspension comprising the therapeutic particle. The present application also provides particles (e.g.

Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.

Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.

Abstract: The present document describes a dosage form for delivery of an active ingredient comprising: a first carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation; alone or in a co-complex with at least one of a) a control release polymer chosen from an insoluble polymer or a polymer having a reduced water solubility at 30° C., and a soluble polymer; and b) a second carboxylated polymer having carboxyl groups complexed with a divalent cation. The document also describes processes of making a carboxylated polymer having carboxyl groups, having a degree of substitution of at least 0.2, a molecular weight of at least 200 kDa, and at least 30% of said carboxyl groups being complexed with a divalent cation, and an inclusion complex, a co-complex, or both comprising the same.

Abstract: An ingestible product is configured to be swallowed by a patient and includes: a drug portion that requires a Risk Evaluation and Mitigation Strategy (REMS) plan; and a wireless sensor portion configured to transmit sensor data concerning the drug portion to a remote device.

Abstract: A bubble manufacturing container of the present invention includes: a container body having an opening portion; and a rubber stopper provided on the opening portion of the container body. The rubber stopper is constituted so that the bubbles 1 of an inside of the container body are able to be taken by piercing an injection needle. It is preferred that the bubble manufacturing container has a fastening portion provided on the rubber stopper, having an opening and sealing the container body with the rubber stopper. Furthermore, it is preferred that the container body mounts a weight portion.

Abstract: The present invention provides a method for effectively utilizing a nanobubble dispersion liquid and/or a microbubble dispersion liquid in medical treatment. In the present invention, the nanobubble dispersion liquid containing nanobubbles that are positively or negatively charged, and that have an average particle size of 10 nm to 500 nm is brought into contact with pathogenic microorganisms, which improves an antibacterial effect against pathogenic microorganisms, and/or the microbubble dispersion liquid containing microbubbles that are positively or negatively charged, having an average particle size of 1 ?m to 900 ?m is brought into contact with the affected area to crush and wash bloody or non-bloody infectious viscous excrement or exudate, or crush and remove a blood clot.

Abstract: A modified nanoparticle for use in a therapeutic method, wherein the therapeutic method comprises the administration of the modified nanoparticle to an organism, the targeting of the modified nanoparticles to a specific site in the organism followed by an uptake of the modified nanoparticle into a cell, and wherein the modified nanoparticle is obtainable by a process comprising the steps of i) providing a nanoparticle and ii) contacting the nanoparticle with one or more antibodies as at a pH value of less than 7.0 so as to non-covalently bind the one or more antibodies via its/their Fc region onto the surface of the nanoparticle, wherein the nanoparticle provided in step i) is made of a material having at least one protonable or deprotonable group on the surface thereof and/or the one or more targeting moieties contacted with the nanoparticle in step ii) has at least one protonable or deprotonable group.

Abstract: The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

Abstract: The present invention relates to electro spun fibers for a local release in the central nervous system of an anti-inflammatory and a promyelinating agent over a defined time-window, in order to limit secondary neurodegeneration triggered by the glutamate release and supported by on-going inflammation. The combined treatment aimed to reduce inflammation and improve remyelination in the very early stage of the pathology improving the chronic clinical outcome of the lesion. In particular the present invention relates to electrospunpolymeric fibers, wherein said fibers are loaded with 3,3,5-Triiodo-L-thyronine (T3) and Ibuprofen.

Abstract: Disclosed herein are bioerodible drug delivery devices including one or more active agents, and related methods. The devices are useful for administering a wide variety of agents over prolonged periods of time.

Abstract: Compositions, devices, and methods for transdermal administration of olanzapine and uses thereof, e.g., to treat nausea and vomiting.

Abstract: A wearable patch for the transdermal delivery of cannabidiol (CBD). Cannabidiol is delivered in in the form of a CBD mixture which comprises CBD oil loaded into liposomes. The CBD mixture can be delivered without the use of dermal enhancers. A transdermal patch is preloaded with the CBD mixture and placed upon the skin to penetrate the dermis layer, where the CBD mixture will diffuse into the interstitial body fluid. The patch comprises microneedles and the CBD mixture which is preloaded into or on the needles depending on the type of microneedles used.

Abstract: A transdermal drug delivery patch includes a flexible base layer, and a plurality of microneedles disposed at one surface of the base layer and including a biodegradable polymer and a drug. Each of a plurality of microneedles is formed as a star-shaped pyramid including a plurality of protrusions extending in a radial direction, and a concave shape is formed between two protrusions adjacent along a circumferential direction among a plurality of protrusions.